Hilleman Laboratories to Invest Rs 300 Crore to Develop Low-cost Vaccines

Delhi-based Hilleman Laboratories announced that it plans to invest around Rs 300 crore in the next 4-5 years to develop low-cost vaccines to treat diseases like cholera and meningitis.

The company is a 50:50 joint venture between MSD Pharmaceuticals and UK-based Wellcome Trust.

World Health Organization Experts Advised To Shift Vaccines Used To Eradicate Polio
The UN health agency warned that the biggest obstacles to eradicating polio were the sporadic outbreaks of the disease caused by live polio virus used in some vaccines.

"We are spending around Rs 300 crore over the next 4-5 years to develop low-cost vaccines. We are developing vaccines to treat rotavirus, cholera and meningitis," said Hilleman CEO Davinder Gill.

"For research, we are looking for partners namely pharma companies, vaccine specialty companies and Government agencies to collaborate and fund the project. We had received foundational grants from MSD Pharmaceuticals and Wellcome Trust, but now we want to be financially independent," he said.

MSD Pharmaceuticals and Wellcome Trust invested around Rs 700 crore nearly five years ago in the company which is now valued at around Rs 900 crore, he added.

Scientists Identify New Strategy To Develop Dengue Vaccines
Scientists have been able to detect antibodies against CRVP379 in human blood samples, demonstrating that it is able to elicit an immune response in humans.

MSD Pharmaceuticals (also known as Merck Sharp & Dohme or MSD in many parts of the world) is an affiliate of Merck & Co Inc. "Normally, there is a large capital investment required for creating vaccines. We, however, have taken an approach that will allow the vaccines to be created at a lesser cost thus providing a boost to manufacturers, who can use synthetic platform technology," Gill said.

The company is developing a synthetic vaccine to fight meningitis in Asian, African and Latin American countries.

Vaccine Use Led to Increasing Number of Polio-Free Countries
As of October 14, a total of 243 polio cases had been reported in 2014, with 92 percent of the cases reported from Nigeria, Afghanistan, and Pakistan.

"We are developing a vaccine for rotavirus, which would be heat-resistant and easy to carry. We have already started clinical trials and it will be ready in 3-4 years," Gill said.

As per the development plan, Medicine in Need, a not- for-profit research organization, will make available the company its formulation technology, while MSD would provide components of its existing rotavirus vaccine, he added.

Parents Begin Deciding Vaccine Preferences Before Pregnancy
A significant majority (72 percent) of parents in the postpartum ward reported starting to develop vaccine preferences for their newborn before conception.

Source-PTI